Trials / Completed
CompletedNCT01049893
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
A Phase 1 Open-Label, Dose Finding, Safety and Tolerability Study of AC220 Administered Daily to Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without food and without any rest periods, as long as there is no evidence of disease progression or unacceptably severe adverse events (AEs) related to the study drug.
Detailed description
A phase 1 open-label, dose finding study of AC220 in patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Compound AC220 | Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-01-15
- Last updated
- 2019-02-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01049893. Inclusion in this directory is not an endorsement.